Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33381678

about

Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia New molecular targets in mantle cell lymphoma Bcl-2 antagonists: a proof of concept for CLL therapy The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Autophagy and endocrine resistance in breast cancer Targeting the apoptosis pathway in hematologic malignancies The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention.Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.Why anti-Bcl-2 clinical trials fail: a solution Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.BH3-only proteins in apoptosis and beyond: an overview.A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Overcoming multiple drug resistance mechanisms in medulloblastoma.Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Molecular targeted approaches in mantle cell lymphoma.Intracellular delivery system for antibody-Peptide drug conjugates Targeted treatment for chronic lymphocytic leukemia.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.Enantioselective synthesis of metacycloprodigiosin via the "Wasserman pyrrole"Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1 CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.Therapeutic advancement of chronic lymphocytic leukemia.Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies

P2860

Q26771601-3F9426A4-15EC-406B-BFED-FCADDDF7A84A Q26781895-80FCBAB6-43B7-4F9E-983C-4322654A1C56 Q26821766-F4EA4EAE-2F76-480E-8F1C-269867349CF6 Q26823996-956748D5-0847-425D-831D-452678DEE54B Q27010154-10B13674-7A1E-407E-9D31-3FCE67DC5DC2 Q27023375-17842DF1-5C03-4075-AB41-BF27F278665C Q27024422-01ED973B-B174-4376-A232-7DF6D49FEBD8 Q28075683-3089D145-D15D-4153-B46E-FD9CE21F3E55 Q30538418-68A59E99-5669-4181-BA23-6FB704A21680 Q33392920-2A101679-C808-4095-A48B-F598EC91464F Q33398808-9DDF8FB8-346D-4064-892B-A9C83A9225D4 Q33414307-D908D789-92A4-4C05-BDC5-A2E97261B41E Q33727248-EC0E639E-684F-469D-8F2D-6EBF5DD214ED Q33755338-0F2ECB86-00DC-4654-B077-B156568D98F4 Q33758493-334B5A13-A27F-43B7-B4B3-E4EFCE3284DB Q34004454-1AE71A95-CA08-48AA-B2C4-5C7C022B865F Q34074715-0A82F6B3-1719-46B6-888C-4273244A7AE2 Q34085370-A9E15FFA-EC55-4870-9BCD-57B11ACE382C Q34155620-E3163E25-2C3D-4D08-878C-CC4C1FE13C42 Q34294097-89ED1507-CE2E-4ECE-9521-3758C34763D9 Q34500602-B1EFDD0E-3259-4AEA-9245-F97C769AF05C Q34763661-1D180BDA-FCF4-45CA-A340-E37ED5879B5B Q34849602-18B48185-7691-481E-947B-83212044E51E Q35007971-9497C821-B6ED-4431-8CDB-BF94635D1AE4 Q35127368-C778CC12-474F-424F-878A-B06F3168A61B Q35594851-BDA6CE35-DFF2-4C5C-BA8C-EE587A233735 Q35599741-6F55E47B-155D-4B3E-9B59-274AAC14404C Q35605318-CB80F92A-DAD6-4C96-9E81-CC1FBBB2A7FB Q35731554-E76676AD-07FA-4255-B540-58BB3DAAD3E0 Q35781697-0D4D5BA0-69E3-4A4A-92C8-DBDDB1CD0879 Q35794457-6D459579-689B-4055-898B-32C1924AA5A8 Q35835203-630FFBDE-B99A-40BA-9486-AAD1D145F1BD Q35860550-B01CC586-AAB8-400E-B7DA-2AE6DEE21300 Q36111609-5EE9EAD1-BB04-4173-A3C8-B17DFE634A61 Q36170136-672CB5B6-7CBA-4599-ACB7-D234564B31BB Q36300303-F6B341BD-5CD1-4B15-81BE-FCA43D342455 Q36337960-9E322A35-A078-477D-A9C2-375FF35051EB Q36541458-1E539BBD-7E62-4AB9-AD57-50C86D214622 Q36601134-DC1C988C-AD7B-4EF8-AF65-D658D192C418 Q36602853-9D0330B3-FC29-46F9-90BC-E3B8303B8D9B

P2860

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33381678

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@ast

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@en

type

label

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@ast

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@en

prefLabel

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@ast

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@en

P1433

Q33381678-B6BF1038-9708-4934-B3A1-8619C4375828

P1476

Q33381678-D57E3A1A-D214-4DB2-851C-42AF3BC7560C

P2093

Q33381678-40935CCB-8A7E-480E-BA80-04508CBFF1A5

Q33381678-612632CF-B4AE-4856-B4D8-BC558719C964

Q33381678-70F4B8D6-34BC-4D4C-BFB6-1CF3D1110978

Q33381678-73614467-BC6C-46CF-9A1D-DCF853CF545D

Q33381678-D1D5866B-7CA8-410B-9291-C1DBEF646D61

Q33381678-E37B5595-C60C-434C-96C7-D51851054C16

P2860

Q33381678-3565D84D-716D-4CAD-8BD2-7D29D5669B59

Q33381678-3A97EBD0-14AE-41B8-9A5C-4BA943F9148D

Q33381678-4E75E30A-0247-46D0-BA01-6936ECB019F1

Q33381678-876C29DE-2B53-4C33-818E-C083516D34E4

Q33381678-8F03470A-A540-4018-922A-F8C61DCF1B66

Q33381678-AC4B51E0-C8B1-4DEB-B00F-BFFB4714733C

Q33381678-B554E77A-C819-4A1E-BA10-CB404A9EF6D1

Q33381678-B585C6AA-E925-4AF4-A55C-E31A0F443B37

Q33381678-E4DCA3F6-2F77-4E1A-93F1-EE5A4EFFC1BC

Q33381678-EBF9C123-657D-48ED-A714-DEA9E9B8D8B2

P304

Q33381678-C8BC7C96-FCB9-4059-BE25-69A08850A879

P31

Q33381678-74610F1F-37B4-427E-AFC0-1DFC0220AC3C

P356

Q33381678-AC5D1FD1-DF07-4ED3-8395-89E425E82199

P407

Q33381678-78608FC5-0213-4EDB-B3FD-FA994BBCC6B5

P433

Q33381678-782E048D-63DE-42FF-80EA-57CA6D118777

P478

Q33381678-A9D2CB84-8C01-4F5E-A135-BA27F6F951DA

P50

Q33381678-BE52C0BB-25D9-4BBC-A910-B5BB831613FF

Q33381678-C498C873-2E39-4651-A2FB-55D019E4A172

P577

Q33381678-FE301ECA-E318-48F3-8B97-3D6F729BA338

P5875

Q33381678-A9C43FE4-0BE1-4A24-9A72-12C70F7252C9

P698

Q33381678-8AF24DEA-5116-4745-9B96-10DFB677C61F

P921

Q33381678-40814E14-5E72-4671-945F-8477EF8CBB09

Q33381678-AD06ED78-6518-4DC0-9DD6-8249054D2903

P932

Q33381678-459287FA-A18A-4E8D-8A79-283F2549DA4F

P356

BLOOD-2008-02-137943

P1433

P1476

Phase I study of obatoclax mes ...... chronic lymphocytic leukemia.

@en

P2093

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

David F Claxton

http://www.w3.org/2001/XMLSchema#string

Jean Viallet

http://www.w3.org/2001/XMLSchema#string

Michael Crump

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

Thomas Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Apoptosis-based therapies for hematologic malignancies.

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission.

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.

Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells.

Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak

P304

299-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-02-137943

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Michael J. Keating

P577

2008-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23394953

http://www.w3.org/2001/XMLSchema#string

P698

18931344

http://www.w3.org/2001/XMLSchema#string

P921

P932

4968372

http://www.w3.org/2001/XMLSchema#string